161 related articles for article (PubMed ID: 29289516)
1. Probing the particulate microstructure of the aerodynamic particle size distribution of dry powder inhaler combination products.
Jetzer MW; Morrical BD; Schneider M; Edge S; Imanidis G
Int J Pharm; 2018 Mar; 538(1-2):30-39. PubMed ID: 29289516
[TBL] [Abstract][Full Text] [Related]
2. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
[TBL] [Abstract][Full Text] [Related]
3. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
4. Particle interactions of fluticasone propionate and salmeterol xinafoate detected with single particle aerosol mass spectrometry (SPAMS).
Jetzer MW; Morrical BD; Fergenson DP; Imanidis G
Int J Pharm; 2017 Oct; 532(1):218-228. PubMed ID: 28864391
[TBL] [Abstract][Full Text] [Related]
5. Experimental and computational study of the effect of breath-actuated mechanism built in the NEXThaler
Farkas Á; Lewis D; Church T; Tweedie A; Mason F; Haddrell AE; Reid JP; Horváth A; Balásházy I
Int J Pharm; 2017 Nov; 533(1):225-235. PubMed ID: 28941830
[TBL] [Abstract][Full Text] [Related]
6. Computer modeling of airway deposition distribution of Foster(®) NEXThaler(®) and Seretide(®) Diskus(®) dry powder combination drugs.
Jókay Á; Farkas Á; Füri P; Horváth A; Tomisa G; Balásházy I
Eur J Pharm Sci; 2016 Jun; 88():210-8. PubMed ID: 26976481
[TBL] [Abstract][Full Text] [Related]
7. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
8. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
[TBL] [Abstract][Full Text] [Related]
9. Can 'extrafine' dry powder aerosols improve lung deposition?
de Boer AH; Gjaltema D; Hagedoorn P; Frijlink HW
Eur J Pharm Biopharm; 2015 Oct; 96():143-51. PubMed ID: 26220014
[TBL] [Abstract][Full Text] [Related]
10. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
Wauthoz N; Hennia I; Ecenarro S; Amighi K
Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
[TBL] [Abstract][Full Text] [Related]
11. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
12. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
Thalberg K; Åslund S; Skogevall M; Andersson P
Int J Pharm; 2016 May; 504(1-2):27-38. PubMed ID: 26965200
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
14. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.
Corradi M; Chrystyn H; Cosio BG; Pirozynski M; Loukides S; Louis R; Spinola M; Usmani OS
Expert Opin Drug Deliv; 2014 Sep; 11(9):1497-506. PubMed ID: 24921434
[TBL] [Abstract][Full Text] [Related]
15. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.
Jõgi R; Lähelmä S; Vahteristo M; Happonen A; Haikarainen J
J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):88-98. PubMed ID: 30300557
[TBL] [Abstract][Full Text] [Related]
16. Limitations of high dose carrier based formulations.
Yeung S; Traini D; Tweedie A; Lewis D; Church T; Young PM
Int J Pharm; 2018 Jun; 544(1):141-152. PubMed ID: 29649519
[TBL] [Abstract][Full Text] [Related]
17. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations.
Guchardi R; Frei M; John E; Kaerger JS
Int J Pharm; 2008 Feb; 348(1-2):10-7. PubMed ID: 17689898
[TBL] [Abstract][Full Text] [Related]
18. The impact of possible improper use on the performance in vitro of NEXThaler in comparison with Ellipta inhaler.
Varacca G; D'Angelo D; Glieca S; Cavalieri L; Piraino A; Quarta E; Sonvico F; Buttini F
Eur J Pharm Sci; 2023 Apr; 183():106385. PubMed ID: 36646153
[TBL] [Abstract][Full Text] [Related]
19. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma.
Bulac S; Cimrin A; Ellidokuz H
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594
[TBL] [Abstract][Full Text] [Related]
20. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers.
James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ
Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
